Farmington, April 17, 2023 (GLOBE NEWSWIRE) -- The Global Digital Breast Tomosynthesis system Market Was Valued At USD 2.4 billion In 2022 And Is Expected To Expand USD 8.1 billion By 2030 at a CAGR Of 14.2% From 2023 To 2030. Cancer is a major health concern globally, and its incidence is increasing. Liquid biopsy offers a non-invasive diagnostic tool for the detection and monitoring of cancer. Technological advancements in liquid biopsy technologies such as next-generation sequencing, polymerase chain reaction (PCR), and microarrays have led to more accurate and sensitive detection of biomarkers in body fluids.
The market for analytics can be further broken down into local markets, which vary by region and country. For example, the North American analytics market is the largest in the world, driven by the presence of major technology companies and a strong culture of innovation. In Europe, the analytics market is also growing, fueled by initiatives such as the European Union's General Data Protection Regulation (GDPR) and increasing adoption of cloud-based analytics solutions.
Request Sample Copy of Report “Digital Breast Tomosynthesis (DBT) System Market Size, Share & Trends Estimation Reports By Type Outlook (2D Digital Mammography Technology, 3D Digital Mammography Technology), By Component Outlook (Hologic, GE Healthcare, Siemens, I.M.S., PLANMED OY, XinRay Systems, FUJIFILM), By Application Outlook (Hospitals,Diagnostic Centres,Others ),By Region and Forecasts,2022-2030.” published by Contrive Datum Insights.
Segmentation Overview:
Digital Breast Tomosynthesis (DBT) System Market Overview
Market Size, Status, and Forecast 2023-2030 for Digital Breast Tomosynthesis (DBT) Systems. Extensive research has been conducted to provide the most recent insights on the most salient characteristics of the global Digital Breast Tomosynthesis (DBT) System market. This report offers a comprehensive analysis of the Digital Breast Tomosynthesis (DBT) System Market, including its drivers, restraints, historical and current trends, regulatory scenarios, and technological advancement. The industry's response to the COVID-19 outbreak was thoroughly evaluated. In a special period, the Digital Breast Tomosynthesis (DBT) System was subjected to a thorough risk assessment and industry recommendations. This report compares the pre-COVID-19 and post-COVID-19 markets. In addition, the research investigates the effects of COVID-19/the Russia-Ukraine War on the regional economy.
Organization Size Outlook:
Digital breast tomosynthesis (DBT) is a cutting-edge technique for detecting breast cancer. Tomosynthesis employs low-dose x-rays to create a three-dimensional image of the breast. Occasionally, the DBT system is also referred to as "digital tomosynthesis" or "tomography." DBT provides a more comprehensive breast image than traditional 2D digital mammography, making it simpler for radiologists to detect small problems and cancers. DBT also helps reduce false positives, which frequently result in unnecessary biopsies. This market is expanding because more individuals are being diagnosed with breast cancer, more individuals want to detect and treat breast cancer early, and digital breast tomosynthesis (DBT) systems continue to improve.
Regional Analysis:
Digital breast tomosynthesis (DBT) devices are anticipated to have a significant market share in North America due to the high demand for new products and the growing popularity of screening methods. The market in this region is primarily driven by the increasing number of women with breast cancer, the research and development of novel breast cancer treatments, and the improvement of breast imaging techniques. According to the International Agency for Research on Cancer, there were approximately 2.54 million breast cancer cases in the region in 2020, and this figure is expected to rise to 3.53 million by 2040. Similarly, the American Cancer Society reported in January 2022 that breast cancer is the most prevalent cancer among women in the United States, with one in three women being diagnosed. According to the American Cancer Society, approximately 2,87,850 new cases of invasive breast cancer will be diagnosed in women in the United States by 2022. Therefore, the market in this sector is driven by the high incidence of breast cancer.
Buy this Premium Research Report@
https://www.contrivedatuminsights.com/buy/75294
Scope of Report:
| Report Attributes | Details |
| Growth Rate | CAGR of 14.2% from 2022 to 2030. |
| Revenue Forecast by 2030 | $8.1 Billion |
| By Deployment Type |
|
| By Organization Size |
|
| By Industries |
|
| By Companies |
|
| Regions and Countries Covered |
|
| Base Year | 2022 |
| Historical Year | 2017-2022 |
| Forecast Year | 2023-2030 |
LATEST TRENDS:
Continuous Technological Innovations to Transform Market Outlook
The Digital Breast Tomosynthesis (DBT) System market is expected to be positively influenced by technological trends driven by increased Rand spending and growing focus on innovation by industry players resulting in novel breakthroughs. Significant opportunities in the forecast period will lead to new players entering the space and the market getting more competitive. Consumer expectations will continue to evolve, which will be met by new product launches with new features or lower price points as top companies focus on maintaining their leadership position and new players try to create a market presence.
Restraining Factors:
There are a number of challenges that could slow the expansion of the global digital breast tomosynthesis management market. Among the most important constraints are:
High Cost and a Bleak Economic Outlook Hamper Demand
The Digital Breast Tomosynthesis (DBT) System Market has been experiencing rapid demand and adoption across various key applications and end-use sectors in recent years. However, the global economy, which has struggled since the pandemic, is forecasted to grow at a slower rate due to the Russia-Ukraine war, rising inflation, and growing interest rates.
All these factors are making consumers vary in making purchases adversely impacting the manufacturing sector and the overall market potential. The high cost of products and availability of alternatives is a key factors limiting its demand and adoption in several regions as well.
Lack of evidence regarding the efficacy of DBT is expected to hamper the growth of the global digital breast tomosynthesis (DBT) devices market. No significant trials have been performed on DBT. These trials require large numbers of participants to demonstrate the substantial benefits of DBT in cancer detection.
Furthermore, increase in interpretation time for radiologists is also expected to hamper the growth of the market. Due to the large number of images generated, the time required to read a DBT image set is almost double that of interpreting a 2D mammogram; approximately 200 images compared to four images for a 2D view.
Opportunity Analysis:
During DBT, patients are exposed to higher levels of radiation than with 2D mammography. Hence, reduction in radiation exposure is expected to offer lucrative growth opportunities for players in the global digital breast tomosynthesis (DBT) devices market.
Regulators also need to define the use of DBT in breast cancer screening (individual and tissue) and its role in the diagnosis and staging of breast cancer (multiple lesions).
In 2021, hospitals held a 64.9% market share, making them the market leaders. Hospitals held a larger share of the digital breast tomosynthesis (DBT) equipment market's end-user segment due to factors such as the increasing number of hospitals and the availability of DBT equipment and related services.
Key Segments Covered:
By Market Players:
- Hologic
- GE Healthcare
- Siemens
- I.M.S.
- PLANMED OY
- XinRay Systems
- FUJIFILM
- Others.
By Deployment Type
- 2D Digital Mammography Technology
- 3D Digital Mammography Technology
- Others
By Application:
- Hospitals
- Diagnostic Centres
- Others
By Industries
- Government
- Healthcare
- Retail
- Manufacturing
- Others
Regions and Countries Covered
- North America: (US, Canada, Mexico, Rest of North America)
- Europe: (Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe)
- Asia-Pacific: (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific)
- The Middle East & Africa: (Saudi Arabia, UAE, Egypt, South Africa, Rest of the Middle East & Africa)
- Latin America: (Brazil, Argentina, Rest of Latin America)
- Rest of the World
Check out more related studies published by Contrive Datum Insights:
- Computer Aided Diagnostics (CADx) Market - The global Computer Aided Diagnostics (CAD) Market size was valued at USD 5.62 Billion in 2022. It is expected to expand at CAGR of 13.3% from 2022 to 2030.
- Blockchain Market - The global blockchain market size is projected to grow from USD 3.0 billion in 2022 to USD 39.7 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 67.3% during the forecast period.
- 5G Infrastructure Market The 5G infrastructure market was valued at USD 1.37 billion in 2020 and is projected to reach USD 42.84 billion by 2030, growing at a CAGR of 54.4% from 2020 to 2030.
Customization of the Report: The report can be customized as per client needs or requirements.For any queries, you can contact us on anna@contrivedatuminsights.com or +1 215-297-4078. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.
Social: Facebook / LinkedIn / Twitter
Contact Us:
Anna B. | Head Of Sales
Contrive Datum Insights
Phone: +91 9834816757 | +1 2152974078
Email: anna@contrivedatuminsights.com
Website:
https://www.contrivedatuminsights.com
Contrive Datum Insights Press Releases
Latest Contrive Datum Insights Latest Reports
